- Home
- KALV
as 08-11-2025 9:52am EST
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 637.9M | IPO Year: | N/A |
| Target Price: | $26.29 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.30 - $16.32 | Next Earning Date: | 09-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 192.67% |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Jun 6 '25 | Sell | $14.50 | 7,169 | $103,950.50 | 315,074 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | May 22 '25 | Sell | $11.31 | 1,926 | $21,781.71 | 98,189 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | May 22 '25 | Sell | $11.31 | 2,146 | $24,271.69 | 113,026 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | May 21 '25 | Sell | $11.88 | 9,999 | $118,743.12 | 315,074 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | May 21 '25 | Sell | $11.88 | 2,317 | $27,515.53 | 98,189 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | May 21 '25 | Sell | $11.88 | 2,689 | $31,933.22 | 113,026 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | May 17 '25 | Sell | $11.84 | 3,808 | $45,097.38 | 315,074 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | May 17 '25 | Sell | $11.84 | 2,600 | $30,791.28 | 98,189 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | May 17 '25 | Sell | $11.84 | 2,776 | $32,875.61 | 113,026 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
CNW Group
2 months ago
Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada
MT Newswires
2 months ago
Sector Update: Health Care Stocks Steady Pre-Bell Thursday
MT Newswires
2 months ago
KalVista Grants Pendopharm Rights to Commercialize its Angioedema Treatment in Canada
Business Wire
2 months ago
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
Investor's Business Daily
2 months ago
How KalVista Pharma Is Taking On A Rare But Deadly Disease
MT Newswires
2 months ago
DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues
Business Wire
2 months ago
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
BioPharma Dive
2 months ago
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.